TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03001024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of WayToServe Español
Description: Following baseline assessment and randomization to experimental condition, premises assigned to the intervention condition will be contacted and recruited to the trial. Managers will provide a list of all servers. All servers will be registered by project staff on the WTS-E website and provided a unique identification code, which will track their use of the training and associate it with the premise. Servers will complete a profile on the program during their first login. Servers will be asked to complete the training within four weeks from initial registration; email and text reminders will be sent to those who do not login within one week of initial registration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual and Customary RBS Training
Description: The premises randomized to the UC training condition will be, in effect, blind to the investigation. Server training is mandatory for all servers in New Mexico. Server training is voluntary in Texas but heavily incentivized by TABC's Safe Harbor clause. Under this clause, liquor licensees are held harmless for any service infractions if all servers are trained and certified by an approved RBS trainer; instead, the server is cited for the infraction.
Study: NCT02495532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lymph node clearing technique with Carnoy solution
Description: Procedure: lymph node clearing technique with Carnoy solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
Study: NCT01358851

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryotherapy
Description: 1-2 times during the treatment time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41005
Description: once daily
Study: NCT00987545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576
Description: QAX576 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QAX576 placebo
Description: Placebo to QAX576 injection
Study: NCT04659720

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolic lifter device
Description: evaluation of implant stability after closed sinus lifting by hydraulic lift technique using hydraulic lifter device

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient satisfaction evalution using hydraulic lifter device
Description: patients satisfaction will be evaluated numerically after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
Study: NCT01549678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total contact insole
Description: EVA insole shaped on patient´s foot.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo insole
Description: EVA insole flat
Study: NCT01512342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pacing
Description: 3 one-on-one sessions weekly for 3 consecutive weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation therapy
Description: 3 one-on-one sessions weekly for 3 consecutive weeks
Study: NCT01741090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell injection
Description: Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.
Study: NCT02315989

Intervention type: RADIATION
Group type: OTHER
Intervention: proton therapy
Description: proton therapy
Study: NCT01274650

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Indirect Calorimetry
Description: Indirect Calorimetry
Study: NCT03626168

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 100% watermelon juice
Description: Participants drank two 12-ounce servings of 100% watermelon juice per day for a four-week period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: Participants drank two 12-ounce servings of a placebo beverage per day for a four-week period.
Study: NCT01620554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: 1 capsule per week during 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: 1 capsule per week during 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: 1 capsule per week during 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: 1 capsule per week during 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per week during 2 weeks
Study: NCT01724879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
Study: NCT01146912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Text message vaccine reminders

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: automated call
Description: Automated call

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: automated call
Description: Automated call
Study: NCT02548533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFXL
Description: Pretreatment at 2.5 mJ/microbeam and 15% density.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES
Description: Topical application on AFXL pretreated skin 15 minutes prior to the treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA cream
Description: Topical application 2 hours prior to the treatment.
Study: NCT01645852

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Optifast 800
Description: Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
Study: NCT02000505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PocketCPR
Description: 5 minutes chest-compression-only CPR, using Zoll PocketCPR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metronome
Description: 5 minutes chest-compression-only CPR, using a metronome

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 110bpm Song
Description: 5 minutes chest-compression-only CPR, using a song with 110bpm for support
Study: NCT03022903

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aminolevulinic Acid (ALA)
Description: Photosensitizing
Study: NCT04545606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person CBT for insomnia in children with autism
Description: 7 modules administered in-person~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote CBT for insomnia in children with autism
Description: 7 modules administered over telehealth/videoconferencing~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote sleep hygiene and related education (SHARE) for insomnia in children with autism
Description: 7 modules administered over telehealth/videoconferencing~1. Sleep Education~2. Sleep Architecture \& Parasomnias~3. Physical Activity \& Sleep~4. Nutrition, My Plate, \& Breathing during Sleep~5. Stress, Sleep, Dreams, \& Nightmares Connections~6. Mood, Self-Esteem, \& Sleep~7. Light \& Dark Cycle
Study: NCT00631917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 10 mg once a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to Ramipril
Description: Placebo capsules to match ramipril.
Study: NCT06638983

Intervention type: OTHER
Group type: OTHER
Intervention: Non-extraction Orthodontic Treatment of Angle Class I Malocclusion
Description: Cephalometric radiographs, and extraoral and intraoral photographs, and cast impressions were collected before and after intervention. The weighted PAR Index (Peer Assessment Rating) employed to determine outcome of orthodontic treatment. Also the following soft tissue and bone indexes were assessed before and after intervention
Study: NCT02277730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vasopressor delivery automated system
Description: vasopressor delivery using phenylephrine and ephedrine
Study: NCT06643221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After an initial maximal graded exercise test to determine maximal oxygen uptake and peak cycling power, healthy participants will undergo a 20-minute graded exercise test at intensities corresponding to 50, 60, 70 and 80% VO2max (5-minutes per stage)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Description: To determine if pharmacological activation of beta-adrenergic receptors evokes an immune respponse akin to exercise, healthy participants will receive an intravenous infusion of isoproterenol (50ng/kg/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy participants will consume the placebo 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bisoprolol Fumarate Tablet 10 mg
Description: Healthy participants will consume a 10mg Bisoprolol Fumerate tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
Description: Healthy participants will consume a 80mg Nadolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol 50 mg
Description: Healthy participants will consume a 50mg Carvedilol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast 500 Mcg Oral Tablet
Description: Healthy participants will consume a 500mcg Roflumilast tablet and a 10mg Bisoprolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
Study: NCT02495532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lymph node clearing technique with Carnoy solution
Description: Procedure: lymph node clearing technique with Carnoy solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lymph node clearing technique with GEWF solution
Description: Procedure: lymph node clearing technique with GEWF solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lymph node clearing technique with GEWF solution
Description: Procedure: lymph node clearing technique with GEWF solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
Study: NCT04157452

Intervention type: PROCEDURE
Intervention: flexible ureteroscopy
Description: flexible ureteroscopy is used to removed the stone. If a double-J stent was inserted pre-operatively, it was removed at the beginning of surgery. Rigid ureteroscopy was routinely used for ureteral dilatation before fURS. A 0.035 mm guidewire was advanced through the urethral and ureteral meatuses to the renal pelvis under direct rigid ureteroscope vision. A 14-Fr ureteral access sheath (Cook Medical, Bloomington, IN) was then passed over the wire to the ureteropelvic junction, and 7.5-Fr fURS (Flex-X2, Karl Storz, Germany) was performed through the sheath. Intrarenal pressure was stabilized by a pressure-sensitive pump (Shenda Medical, China). Holmium: yttrium-aluminum-garnet laser was used to fragment the stones. After lithotripsy, 6-Fr double-J stent was routinely inserted in all cases for 2-4 weeks.
Study: NCT01099306

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical care services
Description: Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
Study: NCT03769831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285
Description: Ascending dose oral adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ascending dose oral adminstration
Study: NCT02939261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention - 4 Home Visits
Description: 4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: monthly emails with general health information
Study: NCT04029454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: birth dose vaccination against hepatitis B strategy
Description: Complex intervention targeting healthcare workers and involving:~* training on hepatitis B awareness and management~* training on EPI vaccination and cold chain~* training on the modalities for the birth dose administration~* the use of a monovalent unidose vaccine against Hepatitis B
Study: NCT03288857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeilMed Naspira
Description: NeilMed Naspira is a nasal-oral aspirator
Study: NCT04258631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Given IT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy
Description: Undergo laparotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparotomy
Description: Undergo laparotomy
Study: NCT02277730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ephedrine
Study: NCT02083172

Intervention type: DEVICE
Intervention: Ultrasound Cardiac Output Monitor and 2 D-Echo
Description: Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.

Intervention type: DEVICE
Intervention: Ultrasound Cardiac Output Monitor and 2 D-Echo
Description: Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.

Intervention type: DEVICE
Intervention: Ultrasound Cardiac Output Monitor and 2 D-Echo
Description: Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
Study: NCT03756337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro 1 & Neuro 2
Description: participant common fitting map used for tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro 2 & Neuro 1
Description: participant common fitting map used for tests
Study: NCT03754387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: Patients choosing AT group were admitted to the hospital for observation and to receive intravenous antibiotics Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) was administered for 3 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: appendectomy
Description: APPT group consisted of admission to the hospital with promptinitiation of intravenous antibiotics and appendectomy
Study: NCT01787110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: see arm description
Study: NCT02063217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: Sodium oxybate h.s.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: 36hr sleep deprivation
Study: NCT00638833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine 30 mg/day (20-10-0)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills
Study: NCT02620059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
Study: NCT00891072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-gossypol acetic acid
Description: Given orally
Study: NCT02277730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ephedrine
Study: NCT00891072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03230734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
Study: NCT02041858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altered Alarm Settings
Description: An altered set of alarm parameter settings
Study: NCT02277730

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manual vasopressor delivery
Study: NCT03605407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient visit prior to hospital admission
Description: Patient and family receiving one visit prior to hospital admission for surgery
Study: NCT01453725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab 50 mg SC injection every 4 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab
Description: Golimumab 50 mg SC injection every 4 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC injection every 4 weeks
Study: NCT00871325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TU-100)
Description: Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TU-100)
Description: Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
Study: NCT02309593

Intervention type: DEVICE
Intervention: PROFEMUR® Xm Femoral Stems
Description: THA using PROFEMUR® Xm Femoral Stems
Study: NCT05059795

Intervention type: DRUG
Intervention: Albumin
Description: Type of resuscitation fluid, dose and use of inotrope
Study: NCT01724931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD-aminopterin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD-aminopterin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04226339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty with a kinetic alignment
Description: During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~it will be set to reproduce the preoperative constitutional deformity in varus or valgus as it was measured before surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with a mechanical alignment
Description: During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~It will be set to 180° as defined for a mechanical femorotibial alignment